Morgan Stanley Maintains Equal-Weight Rating for Rhythm Pharmaceuticals: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
Morgan Stanley has maintained its Equal-Weight rating for Rhythm Pharmaceuticals (NASDAQ:RYTM) and increased its price target from $28.00 to $29.00. Rhythm Pharmaceuticals' shares are currently trading at $23.42, down 0.04% over the last 24 hours. The new price target represents a potential increase of 23.83% from the current share price.
October 10, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Morgan Stanley has maintained its Equal-Weight rating for Rhythm Pharmaceuticals and raised its price target, indicating a potential upside for the stock.
The maintenance of the Equal-Weight rating by Morgan Stanley indicates that the firm believes Rhythm Pharmaceuticals is fairly valued at its current price. However, the increase in the price target suggests that they see potential for the stock's price to rise in the future. This could have a positive impact on the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100